Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative COI-E plus cetuximab for potentially resectable colorectal liver metastases at high risk of recurrence
2008-001062-93Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Apr 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, capecitabine, oxaliplatin and irinotecan in colorectal cancer (CRC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall response rate (ORR) to preoperative regimen. Started Apr 2009; status: completed.
02
Drugs
cetuximabcapecitabineoxaliplatinirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-001062-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001062-93.